Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity

Science Translational Medicine

Volumn 5, Issue 187, 2013, Pages

  Chintalgattu, Vishnu ^a   Rees, Meredith L ^b   Culver, James C ^c   Goel, Aditya ^a   Jiffar, Tilahu ^d   Zhang, Jianhu ^d   Dunner, Kenneth ^d   Pati, Shibani ^b   Bankson, James A ^d   Pasqualini, Renata ^d   Arap, Wadih ^d   Bryan, Nathan S ^b   Taegtmeyer, Heinrich ^b   Langley, Robert R ^d   Yao, Hui ^d   Kupferman, Michael E ^d   Entman, Mark L ^c   Dickinson, Mary E ^c   Khakoo, Aarif Y ^a  

^a AMGEN INC   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CP 673451; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SUNITINIB; THALIDOMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PATIENT; CARDIOTOXICITY; CELL DEATH; CELL FUNCTION; CELL SURVIVAL; CELL TYPE; CONTROLLED STUDY; CORONARY BLOOD VESSEL; DRUG MECHANISM; DRUG TARGETING; HEART STRESS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEOPLASM; NONHUMAN; PERICYTE; PRIORITY JOURNAL; SUNITINIB INDUCED CARDIOTOXICITY;

EID: 84880566944     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3005066     Document Type: Article

References (46)

1. G. Di Lorenzo, R. Autorino, G. Bruni, G. Cartenì, E. Ricevuto, M. Tudini, C. Ficorella, C. Romano, M. Aieta, A. Giordano, M. Giuliano, A. Gonnella, C. De Nunzio, M. Rizzo, V. Montesarchio, M. Ewer, S. De Placido, Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: A multicenter analysis. Ann. Oncol. 20, 1535-1542 (2009).
2. M. Schmidinger, C. C. Zielinski, U. M. Vogl, A. Bojic, M. Bojic, C. Schukro, M. Ruhsam, M. Hejna, H. Schmidinger, Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 26, 5204-5212 (2008).
3. A. Y. Khakoo, C. M. Kassiotis, N. Tannir, J. C. Plana, M. Halushka, C. Bickford, J. Trent II, J. C. Champion, J. B. Durand, D. J. Lenihan, Heart failure associated with sunitinib malate: A multitargeted receptor tyrosine kinase inhibitor. Cancer 112, 2500-2508 (2008).
4. T. F. Chu, M. A. Rupnick, R. Kerkela, S. M. Dallabrida, D. Zurakowski, L. Nguyen, K. Woulfe, E. Pravda, F. Cassiola, J. Desai, S. George, J. A. Morgan, D. M. Harris, N. S. Ismail, J. H. Chen, F. J. Schoen, A. D. Van den Abbeele, G. D. Demetri, T. Force, M. H. Chen, Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370, 2011-2019 (2007).
5. C. J. Richards, Y. Je, F. A. Schutz, D. Y. Heng, S. M. Dallabrida, J. J. Moslehi, T. K. Choueiri, Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J. Clin. Oncol. 29, 3450-3456 (2011).
6. M. L. Telli, R. M. Witteles, G. A. Fisher, S. Srinivas, Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann. Oncol. 19, 1613-1618 (2008).
7. A. Armulik, G. Genové, M. Mäe, M. H. Nisancioglu, E. Wallgard, C. Niaudet, L. He, J. Norlin, P. Lindblom, K. Strittmatter, B. R. Johansson, C. Betsholtz, Pericytes regulate the blood-brain barrier. Nature 468, 557-561 (2010).
8. M. Hellström, M. Kalén, P. Lindahl, A. Abramsson, C. Betsholtz, Role of PDGF-B and PDGFR-b in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126, 3047-3055 (1999).
9. P. Lindahl, B. R. Johansson, P. Levéen, C. Betsholtz, Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277, 242-245 (1997).
10. I. Uraizee, S. Cheng, J. Moslehi, Reversible cardiomyopathy associated with sunitinib and sorafenib. N. Engl. J. Med. 365, 1649-1650 (2011).
11. D. B. Mendel, A. D. Laird, X. Xin, S. G. Louie, J. G. Christensen, G. Li, R. E. Schreck, T. J. Abrams, T. J. Ngai, L. B. Lee, L. J. Murray, J. Carver, E. Chan, K. G. Moss, J. O. Haznedar, J. Sukbuntherng, R. A. Blake, L. Sun, C. Tang, T. Miller, S. Shirazian, G. McMahon, J. M. Cherrington, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/ pharmacodynamic relationship. Clin. Cancer Res. 9, 327-337 (2003).
12. J. O. Haznedar, S. Patyna, C. L. Bello, G. W. Peng, W. Speed, X. Yu, Q. Zhang, J. Sukbuntherng, D. J. Sweeny, L. Antonian, E. Y. Wu, Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: Comparative plasma kinetics in non-clinical species. Cancer Chemother. Pharmacol. 64, 691-706 (2009).
13. B. Speed, H. Z. Bu, W. F. Pool, G. W. Peng, E. Y. Wu, S. Patyna, C. Bello, P. Kang, Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans. Drug Metab. Dispos. 40, 539-555 (2012).
14. V. L. Goodman, E. P. Rock, R. Dagher, R. P. Ramchandani, S. Abraham, J. V. Gobburu, B. P. Booth, S. L. Verbois, D. E. Morse, C. Y. Liang, N. Chidambaram, J. X. Jiang, S. Tang, K. Mahjoob, R. Justice, R. Pazdur, Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin. Cancer Res. 13, 1367-1373 (2007).
15. V. Chintalgattu, D. Ai, R. R. Langley, J. Zhang, J. A. Bankson, T. L. Shih, A. K. Reddy, K. R. Coombes, I. N. Daher, S. Pati, S. S. Patel, J. S. Pocius, G. E. Taffet, L. M. Buja, M. L. Entman, A. Y. Khakoo, Cardiomyocyte PDGFR-b signaling is an essential component of the mouse cardiac response to load-induced stress. J. Clin. Invest. 120, 472-484 (2010).
16. D. P. Stiehl, R. Wirthner, J. Köditz, P. Spielmann, G. Camenisch, R. H. Wenger, Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels. Evidence for an autoregulatory oxygen-sensing system. J. Biol. Chem. 281, 23482-23491 (2006).
17. J. Köditz, J. Nesper, M. Wottawa, D. P. Stiehl, G. Camenisch, C. Franke, J. Myllyharju, R. H. Wenger, D. M. Katschinski, Oxygen-dependent ATF-4 stability is mediated by the PHD3 oxygen sensor. Blood 110, 3610-3617 (2007).
18. C. Willam, P. H. Maxwell, L. Nichols, C. Lygate, Y. M. Tian, W. Bernhardt, M. Wiesener, P. J. Ratcliffe, K. U. Eckardt, C. W. Pugh, HIF prolyl hydroxylases in the rat; organ distribution and changes in expression following hypoxia and coronary artery ligation. J. Mol. Cell. Cardiol. 41, 68-77 (2006).
19. D. May, D. Gilon, V. Djonov, A. Itin, A. Lazarus, O. Gordon, C. Rosenberger, E. Keshet, Transgenic system for conditional induction and rescue of chronic myocardial hibernation provides insights into genomic programs of hibernation. Proc. Natl. Acad. Sci. U.S.A. 105, 282-287 (2008).
20. M. Sano, T. Minamino, H. Toko, H. Miyauchi, M. Orimo, Y. Qin, H. Akazawa, K. Tateno, Y. Kayama, M. Harada, I. Shimizu, T. Asahara, H. Hamada, S. Tomita, J. D. Molkentin, Y. Zou, I. Komuro, p53- induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 446, 444-448 (2007).
21. A. Abramsson, O. Berlin, H. Papayan, D. Paulin, M. Shani, C. Betsholtz, Analysis of mural cell recruitment to tumor vessels. Circulation 105, 112-117 (2002).
22. U. Ozerdem, W. B. Stallcup, Pathological angiogenesis is reduced by targeting pericytes via the NG2 proteoglycan. Angiogenesis 7, 269-276 (2004).
23. U. Ozerdem, K. A. Grako, K. Dahlin-Huppe, E. Monosov, W. B. Stallcup, NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis. Dev. Dyn. 222, 218-227 (2001).
24. K. Higuchi, H. Hashizume, Y. Aizawa, T. Ushiki, Scanning electron microscopic studies of the vascular smooth muscle cells and pericytes in the rat heart. Arch. Histol. Cytol. 63, 115-126 (2000).
25. K. Gaengel, G. Genové, A. Armulik, C. Betsholtz, Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler. Thromb. Vasc. Biol. 29, 630-638 (2009).
26. P. Carmeliet, R. K. Jain, Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 10, 417-427 (2011).
27. W. G. Roberts, P. M. Whalen, E. Soderstrom, G. Moraski, J. P. Lyssikatos, H. F. Wang, B. Cooper, D. A. Baker, D. Savage, D. Dalvie, J. A. Atherton, S. Ralston, R. Szewc, J. C. Kath, J. Lin, C. Soderstrom, G. Tkalcevic, B. D. Cohen, V. Pollack, W. Barth, W. Hungerford, E. Ung, Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Res. 65, 957-966 (2005).
28. F. Lebrin, S. Srun, K. Raymond, S. Martin, S. van den Brink, C. Freitas, C. Bréant, T. Mathivet, B. Larrivée, J. L. Thomas, H. M. Arthur, C. J.Westermann, F. Disch, J. J. Mager, R. J. Snijder, A. Eichmann, C. L. Mummery, Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat. Med. 16, 420-428 (2010).
29. M. S. Gee, S. Makonnen, K. al-Kofahi, B. Roysam, F. Payvandi, H. W. Man, G. W. Muller, W.M. Lee, Selective cytokine inhibitory drugs with enhanced antiangiogenic activity control tumor growth through vascular inhibition. Cancer Res. 63, 8073-8078 (2003).
30. R. S. Bhatt, X. Wang, L. Zhang, M. P. Collins, S. Signoretti, D. C. Alsop, S. N. Goldberg, M. B. Atkins, J. W. Mier, Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol. Cancer Ther. 9, 2793-2802 (2010).
31. M. Jeansson, A. Gawlik, G. Anderson, C. Li, D. Kerjaschki, M. Henkelman, S. E. Quaggin, Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J. Clin. Invest. 121, 2278-2289 (2011).
32. M. Bjarnegård, M. Enge, J. Norlin, S. Gustafsdottir, S. Fredriksson, A. Abramsson, M. Takemoto, E. Gustafsson, R. Fässler, C. Betsholtz, Endothelium-specific ablation of PDGFB leads to pericyte loss and glomerular, cardiac and placental abnormalities. Development 131, 1847-1857 (2004).
33. M. Marini, E. Falcieri, V. Margonato, D. Treré, R. Lapalombella, S. di Tullio, C. Marchionni, S. Burattini, M. Samaja, F. Esposito, A. Veicsteinas, Partial persistence of exercise-induced myocardial angiogenesis following 4-week detraining in the rat. Histochem. Cell Biol. 129, 479-487 (2008).
34. E. A. Winkler, R. D. Bell, B. V. Zlokovic, Central nervous system pericytes in health and disease. Nat. Neurosci. 14, 1398-1405 (2011).
35. S. C. Tang, J. S. Lagas, N. A. Lankheet, B. Poller, M. J. Hillebrand, H. Rosing, J. H. Beijnen, A. H. Schinkel, Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int. J. Cancer 130, 223-233 (2012).
36. F. Fernández-Klett, N. Offenhauser, U. Dirnagl, J. Priller, U. Lindauer, Pericytes in capillaries are contractile in vivo, but arterioles mediate functional hyperemia in the mouse brain. Proc. Natl. Acad. Sci. U.S.A. 107, 22290-22295 (2010).
37. S. Song, A. J. Ewald, W. Stallcup, Z. Werb, G. Bergers, PDGFRb+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat. Cell Biol. 7, 870-879 (2005).
38. G. Bergers, S. Song, N. Meyer-Morse, E. Bergsland, D. Hanahan, Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111, 1287-1295 (2003).
39. L. B. Rivera, A. D. Bradshaw, R. A. Brekken, The regulatory function of SPARC in vascular biology. Cell. Mol. Life Sci. 68, 3165-3173 (2011).
40. K. R. Laderoute, J. M. Calaoagan, P. B. Madrid, A. E. Klon, P. J. Ehrlich, SU11248 (sunitinib) directly inhibits the activity of mammalian 5'-AMP-activated protein kinase (AMPK). Cancer Biol. Ther. 10, 68-76 (2010).
41. R. Kerkela, K. C. Woulfe, J. B. Durand, R. Vagnozzi, D. Kramer, T. F. Chu, C. Beahm, M. H. Chen, T. Force, Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin. Transl. Sci. 2, 15-25 (2009).
42. R. Kerkelä, L. Grazette, R. Yacobi, C. Iliescu, R. Patten, C. Beahm, B. Walters, S. Shevtsov, S. Pesant, F. J. Clubb, A. Rosenzweig, R. N. Salomon, R. A. Van Etten, J. Alroy, J. B. Durand, T. Force, Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 12, 908-916 (2006).
43. R. R. Morrison, X. L. Tan, C. Ledent, S. J. Mustafa, P. A. Hofmann, Targeted deletion of A2A adenosine receptors attenuates the protective effects of myocardial postconditioning. Am. J. Physiol. Heart Circ. Physiol. 293, H2523-H2529 (2007).
44. A. Erez, S. C. Nagamani, O. A. Shchelochkov, M. H. Premkumar, P. M. Campeau, Y. Chen, H. K. Garg, L. Li, A. Mian, T. K. Bertin, J. O. Black, H. Zeng, Y. Tang, A. K. Reddy, M. Summar, W. E. O'Brien, D. G. Harrison, W. E. Mitch, J. C. Marini, J. L. Aschner, N. S. Bryan, B. Lee, Requirement of argininosuccinate lyase for systemic nitric oxide production. Nat. Med. 17, 1619-1626 (2011).
45. A. Sjögren, E. Kristiansson, M. Rudemo, O. Nerman, Weighted analysis of general microarray experiments. BMC Bioinformatics 8, 387 (2007).
46. Y. Hochberg, Y. Benjamini, More powerful procedures for multiple significance testing. Stat. Med. 9, 811-818 (1990).